Celldex Therapeutics (CLDX) EBT Margin (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly EBT Margin of 572686.67% for Q1 2026, down 56367228.0% year-over-year from N/an in Q1 2025, and down 532.14% quarter-over-quarter from 90594.21% in Q4 2025.
Celldex Therapeutics (CLDX) EBT Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' EBT Margin history runs 17 years deep, the most recent figure standing at 572686.67% for Q1 2026.
- In Q1 2026, EBT Margin fell 56367228.0% year-over-year to 572686.67%; the TTM figure through Mar 2026 stood at 37733.6% (down 3112479.0% YoY), while the FY2025 annual figure was 42819.42%, down 3601573.0% from the prior year.
- EBT Margin for Q1 2026 stood at 572686.67%, down from 90594.21% in the prior quarter.
- The five-year high for EBT Margin was 1523.91% in Q3 2024, with the low at 572686.67% in Q1 2026.
- The 5-year median for EBT Margin is 9235.98% (2023), against an average of 50767.35%.
- The sharpest annual moves came in 2025 and 2026: EBT Margin surged 1806510 bps in 2025, then sank 56367228 bps in 2026.
- Celldex Therapeutics' EBT Margin stood at 1642.1% in 2022, then tumbled by 476 bps to 9457.56% in 2023, then tumbled by 206 bps to 28982.81% in 2024, then slumped by 213 bps to 90594.21% in 2025, then slumped by 532 bps to 572686.67% in 2026.
- Business Quant data shows CLDX's EBT Margin at 572686.67% in Q1 2026, 90594.21% in Q4 2025, and 8795.07% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | -340,390.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -340,390.91% |
| Mar 31, 2026 | -572,686.67% |
| Dec 31, 2025 | -90,594.21% |
| Jun 30, 2025 | -8,795.07% |
| Mar 31, 2025 | -9,014.39% |
| Dec 31, 2024 | -28,982.81% |
| Sep 30, 2024 | -1,523.91% |
| Jun 30, 2024 | -1,910.89% |
| Mar 31, 2024 | -27,079.49% |
| Dec 31, 2023 | -9,457.56% |
| Sep 30, 2023 | -2,744.89% |
| Jun 30, 2023 | -12,605.60% |
| Mar 31, 2023 | -3,323.68% |
| Dec 31, 2022 | -1,642.10% |
| Sep 30, 2022 | -6,580.84% |
| Jun 30, 2022 | -22,088.34% |
| Mar 31, 2022 | -13,247.13% |
| Dec 31, 2021 | -6,032.34% |
| Sep 30, 2021 | -13,515.69% |
| Jun 30, 2021 | -384.28% |